A personalized cancer vaccine could be available as soon as 2027. Here’s what we know

Moderna and Merck are preparing to seek regulatory approval after their experimental melanoma vaccine delivered promising results in a late-stage clinical trial. A breakthrough treatment for the deadliest form of skin cancer can cut a patient’s risk of recurrence or death nearly in half.

Source: Fast Company